CVMP започва процедура за сезиране по член 33, параграф 4 на Директива 2001/ 82/ EО, както е изменена.
The Marketing Authorisation Holder was requested to substantiate the bioavailability/ bioequivalence of the product, justifying the efficacy of the product.